1	No difference in retinal fluorescence after oral curcumin intake in amyloid
2	proven AD cases compared to controls
3	
4	
5	Jurre den Haan <sup>1</sup> , MD, PhD, Frederique J. Hart de Ruyter <sup>1</sup> , MD, Benjamin Lochocki <sup>2</sup> ,
6	PhD, Maurice A.G.M. Kroon <sup>3</sup> , PharmD, E. Marleen Kemper <sup>3</sup> , PharmD, PhD,
7	Charlotte E. Teunissen, PhD <sup>4</sup> , Bart van Berckel, MD, PhD <sup>5</sup> , Philip Scheltens, MD,
8	PhD <sup>1</sup> , Jeroen J. Hoozemans, PhD <sup>6</sup> , Aleid van de Kreeke, MD, PhD <sup>7</sup> , Frank D.
9	Verbraak, MD, PhD <sup>8</sup> , Johannes F. de Boer, PhD <sup>2*</sup> , Femke H. Bouwman, MD, PhD <sup>1*</sup> .
10	
11	<sup>1</sup> Amsterdam UMC, location VUmc, Alzheimer Center, Neurology, Amsterdam, The Netherlands,
12	<sup>2</sup> VU Amsterdam, Department of Physics, LaserLaB, The Netherlands
13 14	<sup>3</sup> Amsterdam UMC, location AMC, Department of Pharmacy and Clinical Pharmacology, Amsterdam, The Netherlands.
15	<sup>4</sup> Amsterdam UMC, location VUmc, Neurochemistry lab, Department of Clinical Chemistry, Amsterdam
16	Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands
17	<sup>5</sup> Amsterdam UMC, location VUmc, Department of Nuclear Medicine, Amsterdam, The Netherlands
18	<sup>6</sup> Amsterdam UMC, location VUmc, Department of Pathology, Amsterdam Neuroscience, The
19	Netherlands
20	<sup>7</sup> Amsterdam UMC, location AMC, Ophthalmology Department Amsterdam, The Netherlands
21	<sup>8</sup> Amsterdam UMC, location VUmc, Ophthalmology Department, Amsterdam, The Netherlands
22	<sup>*</sup> Equal contribution.
23	
24	
25 26	
27	
28 29	
30	Corresponding author:
31	Femke Bouwman, MD, PhD
32 33	Alzheimer center Amsterdam, Department of Neurology Amsterdam UMC
34	Mailbox 7057
35 36	1007 MB Amsterdam The Netherlands
37	Phone: +31204440685
38 39	Fax: +31204448529 Email: femke.bouwman@amsterdamumc.nl
39 40	
41	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 43 Abstract

44

## 45 **INTRODUCTION:**

46 Previous work showed the *in-vivo* presence of retinal amyloid in AD patients using

47 curcumin. We aimed to replicate these findings in an amyloid biomarker confirmed

48 cohort.

49

## 50 METHODS:

51 Twenty-six AD patients (age 66 (+9), MMSE≥17) and 14 controls (age 71(+12)) used

52 one of three curcumin formulations: Longvida®, Theracurmin® and Novasol®.

53 Plasma levels were determined and pre- and post- curcumin retinal fluorescence

scans were visually assessed in all cases and quantitatively assessed in a subset.

55

## 56 **RESULTS:**

57 Visual assessment showed no difference between AD patients and controls for pre-

and post-curcumin images. This was confirmed by quantitative analyses on a subset.

59 Mean conjugated plasma curcumin levels were 198.7 nM (Longvida®), 576.6 nM

60 (Theracurmin<sup>®</sup>) and 1605.8 nM (Novasol<sup>®</sup>).

61

# 62 **DISCUSSION:**

63 We found no difference in retinal fluorescence betweenamyloid confirmed AD cases

<sup>64</sup> and control participants, using Longvida<sup>®</sup> and two additional curcumin formulations.

65 Additional replication studies in amyloid confirmed cohorts are needed to assess the

66 diagnostic value of retinal fluorescence as an AD biomarker.

67

### 69 Background

70 Alzheimer's disease (AD) research over the last decades enabled clinicians to diagnose AD not only in the dementia end-stage but also in the prodromal and 71 72 preclinical stages using biomarkers for amyloid, tau and neurodegeneration [1, 2]. AD pathology starts 15-20 years before symptom onset and is reflected by change of 73 74 biomarkers in the preclinical stage [1]. This time-interval provides a window of 75 opportunity for disease modifying drugs to potentially halt disease progression 76 towards the end stage of AD: dementia [3]. As currently used biomarkers are time 77 consuming, expensive and/or invasive, non-invasive easily accessible biomarkers are 78 urgently needed to diagnose AD in the earliest stages, enabling timely selection of patients for trials and future medication. 79

The retina is an extension of the central nervous system and might provide such a 80 81 biomarker. As such the retina is increasingly studied for manifestations of AD as potential non-invasive AD biomarkers. For example, retinal thinning, changes in 82 retinal vasculature and peripheral drusen have been described in AD patients [4-6]. 83 More specifically related to AD pathology, three small studies reported visualization 84 of retinal amyloid beta deposits in-vivo using curcumin, a polipotent polyphenol with 85 86 fluorescent properties that binds to amyloid in post-mortem brain tissue [7-9]. The presence of retinal amyloid beta deposits is however not unequivocally proven, since 87 we and other groups could not confirm amyloid beta deposits in post mortem retinal 88 89 tissue [10-14]. Moreover, curcumin is known for its low bioavailability, and while several commercially available formulations enhancing curcumin plasma levels are 90 on the market, so far only one formulation (Longvida<sup>®</sup>) has been reported to visualize 91 92 retinal amyloid[7].

In the current study, we used three different curcumin formulations as labeling 93 94 fluorophores in-vivo. Using a targeted fluorescence approach, we aimed to visualize 95 retinal amyloid in a well-characterized and amyloid biomarker confirmed AD cohort. 96 97 98 **Methods** 99 Participants We enrolled 26 patients with AD (MMSE score  $\geq$ 17) and 14 controls (MMSE  $\geq$ 27) 100 from two different cohorts - the Alzheimer Dementia Cohort (ADC) and the EMIF-AD 101 102 PreclinAD study. All subjects underwent extensive screening according to a standardized protocol described elsewhere [15, 16]. All patients fulfilled NIA-AA 103 104 criteria of AD with amyloid biomarker confirmation through either CSF amyloid beta<sub>1</sub>-105 42 (Aβ<sub>42</sub>) analysis or amyloid-PET [1]. ADC controls had subjective cognitive decline, 106 defined as cognitive complaints without objective cognitive impairment on 107 neuropsychological exam, no signs of neurodegeneration on neuroimaging, and 108 absence of AD pathology based on CSF biomarkers and/or amyloid-PET. Exclusion criteria for all participants were ophthalmological conditions interfering with retinal 109 110 scan quality, e.g. diabetic retinopathy, glaucoma or moderate/intermediate age 111 related macular degeneration. In addition, we excluded subjects with ischemic stroke 112 and/or mild to severe white matter hyperintensities on MRI, operationalized as a 113 Fazekas score >2. We excluded two AD patients; one because of problems with eye 114 fixation due to visuoperceptive dysfunction and one because of participation in a drug 115 trial with disease modifying drugs. We excluded two controls; one due to problems finishing the scan protocol because of dry eyes and one was found to have 116

117 glaucoma. Three AD patients were lost to follow up. This study was designed and

- 118 conducted according to the Declaration of Helsinki and the study protocol was
- approved by the Ethical Committee of the VU University Medical Center. All patients
- 120 gave their written informed consent in the presence of their caregiver.
- 121
- 122 Amyloid biomarker assessment
- 123 Between 2016 and 2018, CSF concentrations of A $\beta_{42}$ , total tau, and tau
- 124 phosphorylated at threonine 181 (pTau<sub>181</sub>) were measured using Innotest ELISAs
- 125 (Fuijirebio, Ghent, Belgium). Between 2018 and 2020, these CSF biomarkers were
- 126 assessed using Elecsys Aβ<sub>1-42</sub> CSF, Elecsys total-tau CSF, and Elecsys pTau<sub>181</sub>
- 127 CSF electrochemiluminescence immunoassays (Roche Diagnostics, Basel,
- 128 Switzerland). For comparability Innotest CSF values were converted using previously
- published conversion formulas [17]. A pTau/ Aβ42-ratio≥0.020 was considered an AD
- 130 profile [18].
- 131 Amyloid-PET scanning was performed with either <sup>18</sup>F-Florbetaben (NeuraCeq), <sup>18</sup>F-
- 132 Florbetapir (Amyvid) or 18F-Flutemetamol (Vizamyl) tracers [19-21]. An experienced
- 133 nuclear physician (BvB) who completed training for all radiotracers visually assessed

images of amyloid-PET scans as positive or negative.

- 135
- 136 Ophthalmological assessment

Subjects underwent the following general eye examination: best corrected visual acuity (VA), intraocular pressure (IOP) using non-contact tonometry, and slit-lamp examination of the anterior and posterior segment, followed by administration of tropicamide 0.5% to dilate the pupil for optimal retinal imaging. An experienced ophthalmologist (FDV) interpreted all examinations.

# 143 Heidelberg HRA SLO imaging

144	Retinal fluorescence imaging was performed with a Heidelberg Engineering
145	Spectralis Spectral Domain Scanning Laser Ophthalmoscope, at a 486nm
146	wavelength (blue autofluorescence) laser source to excite fluorescence, in
147	combination with a long-pass 500 filter (high transmission in 498-760nm and 800-
148	835nm). Optical resolution was 12 $\mu m$ with a 55° lens, and 6 $\mu m$ with a 30° lens. For
149	each final image an average of 50 frames was used with a sensitivity >90.
150	
151	Curcumin administration and timing of fluorescence imaging
152	Three different oral formulations of curcumin were used:
153	1. Longvida <sup>®</sup> Solid-Lipid Curcumin Particle (Verdure Sciences <sup>®</sup> ), was given in a
154	dosage of 4000 mg per day for 10 consecutive days to 14 AD patients and 12
155	controls [7]. Here we used a 30° lens to acquire images in six regions of interest
156	(ROI) (central macula, superior, temporal, inferior, superior-temporal and inferior-
157	temporal) at baseline and 2-4 hours after the 10th day of curcumin intake (Figure 1A-
158	В).
159	2. Theracurmin $^{\ensuremath{\mathbb{R}}}$ (Theracurmin; Theravalues, Tokyo, Japan), was given in a dosage
160	of 180 mg for 5 consecutive days to 7 AD patients and 2 controls [22, 23]. Here we
161	acquired images using a 30° lens in three ROI's (central macula, optic nerve head
162	(ONH) and temporal) at four different time points: i) at baseline, ii) after four days of
163	curcumin intake, iii) 1 hour after the fifth dose, and iv) 2 hours after the fifth dose
164	(Figure 1 A-B).

3. Novasol<sup>®</sup> (AQUANOVA AG, Darmstadt, Germany), was given in a dosage of 300
mg for 4 consecutive days and a final dose of 500 mg on day 5 to 5 AD patients [24,
25]. With Novasol we acquired images using a 55° lens in six ROI's (central macula,

superior, temporal, inferior, superior-temporal and inferior-temporal) at baseline and 2
hours after the fifth dose (Figure 1A-B).

170

171 Retinal fluorescence image analysis

Baseline and post-curcumin-administration images were assessed both visually and 172 173 quantitatively. Visual assessment was performed by an experienced ophthalmologist. 174 masked for diagnosis and curcumin treatment (FDV). Baseline and post-curcumin-175 administration images of AD patients were compared for the Novasol cohort and also between AD and control subjects for the Theracurmin and Longvida cohort. To 176 support the visual assessment, we used the Longvida® cohort for quantitative 177 analysis, allowing comparison to previous publications using Longvida<sup>®</sup> as curcumin 178 179 derivative. Images of the right eve with sufficient image quality (scans that were out 180 of focus, had extensive shading or extreme low/high contrast hampering coregistration were excluded) were assessed for guantitative analysis (Figure 1C). 181 182 Retinal fluorescence imaging yielded 8-bit grayscale images sized 1536 x 1566 or 183 768 x 798 pixels with a resolution of 6 or 12 µm respectively per pixel. The non-184 normalized, uncompressed images were compared between time points using 185 MATLAB 2020b (MathWorks). An image pair of two time points of similar ROI's were cropped to a size of 1430 x 1430 or 715 x 715 pixels to remove the manufacturer 186 logo and blurry edges. In the case any image pair contained high resolution images 187 (1430 x 1430) the images were down-sampled to match the size of 715 x 715 pixels. 188 189 Afterwards, both images were flat-field corrected to compensate for any illumination 190 and shading effect. A registration algorithm (feature-based registration (SURF: 191 Speeded-Up Robust Features) with affine transformation, allowing for rotation) was used to register matched images [26]. If an automatic match was not obtained, the 192

193 software interrupted and allowed for manual picking of identical points of interest in 194 both images and creating a registration match based on the user's input (using the same registration algorithm). Registered images were cropped to a size of 512 x 512 195 196 pixels, ensuring that both images overlapped within the imaged field of view. Brightness histograms of both images were obtained and matched (using a cubic 197 198 polynomial) to the histogram of the baseline image, resulting in images with similar 199 contrast and overall brightness. We defined focal retinal hyperfluorescence, by 200 selecting areas of  $\geq$ 4 adjacent pixels that represented the 10% highest pixel value in 201 the post-curcumin image. These hyperfluorescence spots were labeled, and their 202 area and brightness measured. The same properties were measured in the baseline 203 image, using the exact same spots (as identified in the post-curcumin image). 204 Afterwards, the brightness difference between each hyperfluorescence spot was 205 calculated.

206

### 207 Curcuminoids plasma level analysis

208 Blood was drawn in heparinized tubes that were directly kept in aluminum foil on ice, 209 to avoid degradation by light and temperature. Within 30 minutes, plasma and serum 210 were separated and plasma was stored at minus 80°C in the Amsterdam UMC 211 Biobank. High Performance Liquid Chromatography-Tandem Mass Spectroscopy (HPLC-MS-MS) analysis was performed to measure different curcuminoids: 212 213 curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin. 214 Each sample was treated, in duplicates, with and without  $\beta$ -glucuronidase after which 215 unconjugated and conjugated curcuminoids were guantified. Treatment with β-216 glucuronidase hydrolyzes the conjugated curcuminoids leading to an increase in 217 unconjugated curcuminoids, whereas untreated samples were guantified on

unconjugated curcumin at that point of time. Our validated method of analysis can be 218 219 described, in short, as follows: Liquid-liquid extraction with Tert Butyl Methyl Ether (TBME) was used to extract the compounds from the plasma [27]. The HPLC-MS/MS 220 221 system consisted of an Ultimate 3000 autosampler and pump, both of Dionex, connected to a degasser from LC Packings. The autosampler, with a 100 µL sample 222 223 loop, was coupled to an Sciex API4000 mass spectrometer. A total of 50 µL sample 224 was injected after which separation of the analytes was performed with an Agilent column 2.1x100mm packed with material of Zorbax Extend 3.5 µm C-18. The 225 flowrate was 0.200µL/min and the dual gradient mobile phase consisted of A: ultra-226 227 purified H2O with 0.1% formic acid and B: MeOH 100%. The applied gradient profile started at 50:50 A:B and increased linear to 95% B in 3.0 minutes. During 6 minutes 228 229 a 5:95 A:B level is continued, after which it returned in 0.2 minutes to 50:50. 230 Afterwards the system was equilibrated during 6 minutes at the starting level. Throughout the liquid-liquid extraction and HPLC-MS/MS the potential influence of 231 232 light brought back to a minimum by working in a dark environment. Each analytical 233 run included a set of freshly prepared calibration samples containing all compounds 234 in the validated range of 2 nM to 400 nM. Each compound was validated with its own 235 deuterated internal standard.

236

237 Statistical analysis

SPSS version 26.0 (IBM, Armonk, NY, USA) was used to assess group differences in
demographics, curcumin data and quantitative retinal fluorescence. Chi squared test
was used for dichotomous variables, independent sample T-test was used for
continuous variables that were normally distributed and Mann Whitney U Test was
used for non-normal distributed variables. Quantitative comparison of focal retinal

243 hyperfluorescence between AD patients and controls was assessed by calculating

the number of focal retinal hyperfluorescent pixels defined as a value in the top 10%

value range at baseline and after curcumin, for all retinal regions of the right eye.

246 Between group differences were assessed using a Mann Whitney U test.

- 247 Significance level for all tests was set at 0.05.
- 248

### 249 Results

250 Group demographics of AD and control cases are shown in table 1, and

supplemental table 1 shows data for each individual participant. The control group

comprised more female participants. No differences were found for age between AD

and control group. As expected, and by design, we found significant group

differences for MMSE as well as CSF and amyloid-PET biomarkers. Table 2A shows

the demographics of the sub group used for the quantitative analysis. No statistical

group differences in age and sex were found.

257

### 258 Qualitative and quantitative retinal fluorescence analysis

No scans were excluded for the qualitative analysis. The qualitative assessment of images pre- and post-curcumin intake by an experienced ophthalmologist (FDV) masked for the clinical diagnosis did not show differences in focal hyperfluorescence in the ROI's, for either AD patients (Longvida<sup>®</sup>, Theracurmin<sup>®</sup> and Novasol<sup>®</sup>) or controls (Longvida<sup>®</sup> and Theracurmin<sup>®</sup>)(Figure 2 and supplemental Figures 1 and 2).

264 The Longvida<sup>®</sup> cohort was used for quantitative analysis. For the quantitative

- analysis one out of 12 control cases (case #10, see Supplemental Table 1) was
- excluded, as our algorithms were unable to find a good registration between time
- points. This applied to a total of 24 regions of a total of 10 patients, while the other

268	regions (n=132) could be included in the analysis. All 14 AD cases that used
200	
269	Longvida <sup>®</sup> were included in the quantitative analysis. While we did find an overall
270	increased fluorescence after curcumin intake (data not shown), no differences were
271	found between diagnostic groups in the number of spots with increased or decreased
272	fluorescence after curcumin intake for all ROIs (all p-values>0.3) (Table 2B).
273	
274	Curcuminoids plasma level analysis
275	HPLC-MS/MS analysis of plasma samples showed detectable levels of free curcumin
276	in blood around the detection level (2 nM) after Longvida®, Theracurmin® or Novasol®
277	intake in all 40 subjects, however there were no significant differences between
278	groups. After treating the samples with $\beta$ -glucuronidase, catalyzing the separation of
279	curcumin from glucuronide and sulfate conjugates, curcumin levels were higher
280	(Table 3). The total mean of curcuminoids was 156.2 nM ( $\pm$ 169.9) after Longvida <sup>®</sup> ,
281	576.6 nM (±211.1) after Theracurmin <sup>®</sup> and 1605.8 nM (±524.6 nM) after Novasol <sup>®</sup>
282	(Figure 3). There were no differences in plasma levels between diagnostic groups (p
283	>0.3, data not shown).

284

# 285 Discussion

In this study we aimed to discriminate AD patients from controls with a targeted
fluorescence approach of the retina using curcumin as fluorophore in a wellcharacterized AD biomarker confirmed cohort. Using three different curcumin
formulations, we did not find differences in focal retinal hyperfluorescence before or
after curcumin intake between diagnostic groups, despite an observed overall
increase in retinal fluorescence after curcumin intake.

292 Our negative findings may be explained by a low intensity of the fluorescent signal 293 resulting from (amyloid-bound) curcumin, insufficient binding of unconjugated 294 curcumin to retinal amyloid, absence of retinal amyloid (in this subset of patients) or 295 methodological limitations of our scanning and analysis methods.

296

297 Fluorescence of curcumin largely overlaps with autofluorescence of the retina. This 298 might therefore mask subtle signals of curcumin fluorescence hypothesized to be the 299 result of retinal amyloid (plaque) pathology, reported to be approximately 5-20µm in size [7]. At present no data is available describing the magnitude of fluorescent signal 300 301 that can be expected from retinal amyloid relative to retinal autofluorescence. On visual inspection we could identify a certain number of hyperfluorescent spots (Figure 302 303 3, zoom-ins), however there was no difference between AD patients and controls in 304 these spots, either in size or intensity, neither at baseline, nor after curcumin intake. To increase sensitivity for weak retinal fluorescent signal possibly overlooked by 305 306 visual inspection, we performed a quantitative analysis on a subset of participants (14 307 AD, 11 controls) who received Longvida confirming findings of the visual inspection.

308

309 The absence of a fluorescent signal after curcumin intake could also be explained by 310 insufficient curcuminbinding to retinal amyloid due to low plasma levels of unconjugated curcumin. After deconjugation using  $\beta$ -glucuronidase we observed 311 high blood levels of total curcumin, in line with previous studies [22, 24]. In contrast, 312 313 Koronyo et al. found high levels of unconjugated curcumin (400nM) without using β-314 glucuronidase [7]. This could be attributed to their different analysis methods: 1. wider/broader calibration settings. 2. internal standards without deuterated forms and 315 validated in mouse. 3. acidification instead of freezing to stabilize samples . 316

317 Nevertheless, conjugated forms of curcumin are known to bind to amyloid as well 318 following ex-vivo application to post-mortem brain sections [28]. And penetration of curcumin in the retina is suggested by our quantitative analysis where a general 319 320 increase in fluorescence was observed after curcumin intake (data not shown), implying that curcumin with the capacity to bind fibrillar amyloid reached the retina. 321 322 Despite 3-4 times higher plasma levels of curcumin conjugates using Theracurmin<sup>®</sup> and Novasol<sup>®</sup> compared to Longvida<sup>®</sup> in this study, we found no difference in focal 323 324 retinal hyperfluorescence between AD patients and controls.

325

326 The lack of between-group differences in our study could also be explained by absence of amyloid in the retina. The presence of (fibrillar) amyloid in the human 327 retina is not unequivocally proven, as three labs showed positive staining with 6E10 328 329 and 12F4 antibodies interpreted as presence of retinal amyloid plaques in postmortem retinas, while others were unable to replicate these findings [7, 10, 12, 13, 330 331 29, 30]. Methodological heterogeneity in post-mortem study methods might account 332 for these discrepancies. Replication studies and harmonization of study methods are 333 needed to overcome these discrepancies before the presence of retinal amyloid in 334 AD can undoubtedly be confirmed. This is one of the key goals of 'The Eye as a 335 Biomarker for AD' Personal Interest Area of the Alzheimer's Association.

336

Three previous studies showed hyperfluorescence in AD cases after curcumin intake
[7-9]. While these studies were of similar small sample size, AD biomarker
confirmation was lacking, which is essential when relating retinal changes to AD,
since other structures may cause changes in fluorescence as well. For example,
retinal drusen, associated with macular degeneration, contain amyloid and other age-

related deposits [31, 32]. This may account for the positive findings in Koronyo's
study where AD patients had a mean age of 76 years compared to 53 years in
controls [7]. More work is needed to discriminate normal aging from pathological
neurodegenerative changes in the retina underlying the observed changes in retinal
fluorescence.

347

348 There are some limitations of this study, potentially explaining the negative findings. 349 First, our scan timing might have been suboptimal for measuring curcumin bound to 350 retinal amyloid resulting in impaired sensitivity. The optimal time point to measure 351 retinal fluorescence is still to be determined. We based our scan timing on previously published pharmacokinetic curves of systemically available curcumin representing 352 assumed peak levels of systemic curcumin, as has been shown to yield signal before 353 354 [7, 22-25]. Second, the quantitative analysis could not be applied on the full cohort because of variation in imaging protocols. Also the fluorescent signal itself, is directly 355 356 affected by illumination differences within images and between time points. These 357 small alterations in scan quality may affect the co-registration of baseline and follow 358 up scans and the signal itself. We applied several algorithms correcting for 359 differences in illumination and scan quality. We are open to sharing our raw data, 360 enabling application of other algorithms.

361

In conclusion, we found no differences in focal retinal hyperfluorescence between AD
patients and controls pre- and post-curcumin, using Longvida<sup>®</sup>, a curcumin
formulation previously used for this purpose. As we could not replicate previous
findings with similar methods in our amyloid biomarker-confirmed cohort, we question
whether focal retinal hyperfluorescence represents retinal amyloid, or rather age-

- 367 related changes. Based on our analysis, retinal hyperfluorescence imaging using
- 368 oral curcumin as labeling fluorophore is currently not ready for use as AD biomarker.

#### References 370

- 371 1. Jack, C.R., Jr., et al., NIA-AA Research Framework: Toward a biological 372 definition of Alzheimer's disease. Alzheimers Dement, 2018. 14(4): p. 535-373 562.
- Sperling, R.A., et al., Toward defining the preclinical stages of Alzheimer's 374 2. 375 disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. 376 377 Alzheimers Dement, 2011. 7(3): p. 280-92.
- Scheltens, P., et al., Alzheimer's disease. Lancet, 2021. 397(10284): p. 1577-378 3. 379 1590.
- 380 Alber, J., et al., Developing retinal biomarkers for the earliest stages of 4. 381 Alzheimer's disease: What we know, what we don't, and how to move forward. 382 Alzheimers Dement, 2020. 16(1): p. 229-243.
- 383 5. Gupta, V.B., et al., Retinal changes in Alzheimer's disease- integrated 384 prospects of imaging, functional and molecular advances. Prog Retin Eye Res, 2021. 82: p. 100899. 385
- Snyder, P.J., et al., Retinal imaging in Alzheimer's and neurodegenerative 386 6. 387 diseases. Alzheimers Dement, 2021. 17(1): p. 103-111.
- Koronyo, Y., et al., Retinal amyloid pathology and proof-of-concept imaging 388 7. trial in Alzheimer's disease. JCI Insight, 2017. 2(16). 389
- 390 8. Tadokoro, K., et al., Retinal Amyloid Imaging for Screening Alzheimer's 391 Disease. J Alzheimers Dis, 2021.
- Ngolab, J., et al., Feasibility study for detection of retinal amyloid in clinical 392 9. 393 trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) 394 trial. Alzheimers Dement (Amst), 2021. 13(1): p. e12199.
- 395 10. den Haan, J., et al., Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas. Acta Neuropathol Commun. 2018. 6(1): p. 147. 396
- 397 11. Jiang, J., et al., Amyloid Plaques in Retina for Diagnosis in Alzheimer's 398 Patients: a Meta-Analysis. Front Aging Neurosci, 2016. 8: p. 267.
- 12. 399 Williams, E.A., et al., Absence of Alzheimer Disease Neuropathologic 400 Changes in Eyes of Subjects With Alzheimer Disease. J Neuropathol Exp 401 Neurol, 2017. 76(5): p. 376-383.
- 402 13. Ho, C.Y., et al., Beta-amyloid, phospho-tau and alpha-synuclein deposits 403 similar to those in the brain are not identified in the eyes of Alzheimer's and 404 Parkinson's disease patients. Brain Pathol, 2014. 24(1): p. 25-32.
- 405 14. Schon, C., et al., Long-term in vivo imaging of fibrillar tau in the retina of 406 *P301S transgenic mice.* PLoS One, 2012. **7**(12): p. e53547.
- 407 15. Konijnenberg, E., et al., The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimers Res Ther, 2018. 10(1): p. 75. 408
- van der Flier, W.M. and P. Scheltens, Amsterdam Dementia Cohort: 409 16. 410 Performing Research to Optimize Care. J Alzheimers Dis, 2018. 62(3): p. 1091-1111. 411
- 412 17. Willemse, E.A.J., et al., Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, 413 multicenter memory clinic cohort: The ABIDE project. Alzheimers Dement 414 415 (Amst), 2018, 10; p. 563-572,
- Willemse, E.A.J., et al., Comparing CSF amyloid-beta biomarker ratios for two 416 18. 417 automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimers Dement (Amst), 2021. 13(1): p. e12182. 418

419	19.	Barthel, H., et al., Cerebral amyloid-β PET with florbetaben (18F) in patients
420		with Alzheimer's disease and healthy controls: a multicentre phase 2
421		<i>diagnostic study.</i> Lancet Neurol, 2011. <b>10</b> (5): p. 424-35.
422	20.	Clark, C.M., et al., Use of florbetapir-PET for imaging beta-amyloid pathology.
423		JAMA, 2011. <b>305</b> (3): p. 275-83.
424	21.	Curtis, C., et al., Phase 3 trial of flutemetamol labeled with radioactive fluorine
425		18 imaging and neuritic plaque density. JAMA Neurol, 2015. 72(3): p. 287-94.
426	22.	Kanai, M., et al., A phase I study investigating the safety and
427		pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer
428		patients. Cancer Chemother Pharmacol, 2013. 71(6): p. 1521-30.
429	23.	Sasaki, H., et al., Innovative preparation of curcumin for improved oral
430		<i>bioavailability.</i> Biol Pharm Bull, 2011. <b>34</b> (5): p. 660-5.
431	24.	Schiborr, C., et al., The oral bioavailability of curcumin from micronized
432		powder and liquid micelles is significantly increased in healthy humans and
433		differs between sexes. Mol Nutr Food Res, 2014. 58(3): p. 516-27.
434	25.	Kocher, A., et al., Highly bioavailable micellar curcuminoids accumulate in
435		blood, are safe and do not reduce blood lipids and inflammation markers in
436		moderately hyperlipidemic individuals. Mol Nutr Food Res, 2016. 60(7): p.
437		1555-63.
438	26.	Bay, H., T. Tuytelaars, and L. Van Gool. SURF: Speeded Up Robust Features.
439		in Computer Vision – ECCV 2006. 2006. Berlin, Heidelberg: Springer Berlin
440		Heidelberg.
441	27.	Kroon, M.A.G.M.v.L., H.W.M.; Swart, E.L. Kemper, E. Marleen; van Tellingen,
442		Olaf, A Validated Hplc-Ms/Ms Method for Simultaneously Analyzing
443		Curcuminoids, Tetrahydrocurcumin and Piperine in Human Plasma, Urine or
444		Feces. Available at SSRN: https://ssrn.com/abstract=4077493 or
445		http://dx.doi.org/10.2139/ssrn.4077493. SSRN, 2022.
446	28.	den Haan, J., et al., Different curcumin forms selectively bind fibrillar amyloid
447		beta in post mortem Alzheimer's disease brains: Implications for in-vivo
448		<i>diagnostics.</i> Acta Neuropathol Commun, 2018. <b>6</b> (1): p. 75.
449	29.	Grimaldi, A., et al., Neuroinflammatory Processes, A1 Astrocyte Activation and
450		Protein Aggregation in the Retina of Alzheimer's Disease Patients, Possible
451		Biomarkers for Early Diagnosis. Front Neurosci, 2019. 13: p. 925.
452	30.	Tsai, Y., et al., Ocular changes in TgF344-AD rat model of Alzheimer's
453		disease. Investigative ophthalmology & visual science, 2014. 55(1): p. 523-
454		534.
455	31.	Luibl, V., et al., Drusen deposits associated with aging and age-related
456		macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest,
457		2006. <b>116</b> (2): p. 378-85.
458	32.	Bergen, A.A., et al., On the origin of proteins in human drusen: The meet,
459		greet and stick hypothesis. Prog Retin Eye Res, 2019. 70: p. 55-84.
460		
-		

# **Authors' contributions**

Author	Contributions
Jurre den Haan	Literature search, study design, data collection, data
	analysis, data interpretation, figures, writing-original draft.
	Verified data.
Frederique Hart de	Data collection, data analysis, data interpretation, writing-
Ruyter	review and editing
Benjamin Lochocki	Image analysis, quantitative data analysis, data
	interpretation, writing-review and editing
Maurice A.G.M.	Data collection plasma analysis, data analysis, data
Kroon	interpretation, writing-original draft
Marleen E. Kemper	Methodology plasma analysis, writing-review and editing,
	supervision
Charlotte E.	Biomarker data interpretation, writing-review and editing
Teunissen	
Bart van Berckel	Biomarker data interpretation, writing-review and editing
Philip Scheltens	Funding acquisition, writing-review and editing
Jeroen J.	Data interpretation, writing-review and editing
Hoozemans	
Aleid Kreeke	Data collection
Frank D. Verbraak	Methodology, study design, image data collection, data
	analysis, data interpretation, writing-review&editing.
	Verified data.
Johannes F. de Boer	Funding acquisition, methodology, study design, data
	interpretation, writing-review and editing. Verified data.
Femke H. Bouwman	Funding acquisition, study design, data analysis, data
	interpretation, writing-original draft. Verified data.

465

### 466 **Conflicts of interest**

Research of CT is supported by the European Commission (Marie Curie International 467 468 Training Network, grant agreement No 860197 (MIRIADE), and JPND), Health 469 Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery 470 Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer 471 Association. CT is recipients of ABOARD, which is a public-private partnership 472 receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance: #LSHM20106). More than 30 partners 473 participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and 474 475 Gieskes-Strijbisfonds. CT has a collaboration contract with ADx Neurosciences, 476 Quanterix and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP 477 478 Pharma, Eisai, PeopleBio, Roche, Toyama, Vivoryon. FB has a collaboration 479 contract with Biogen, Optina Dx and Roche. Payments are made to the institution of 480 VUMC. FB is committee member of EAN and chairs the atypical AD PIA and the Eye 481 as biomarker for AD PIA of ISTAART. PS is chair steering committee in NOVARTIS, 482 member DSMB GENENTECH, global PI phase s! study AC IMMUNE, member advisory board AXON NEUROSCIENCE, global PI phase 2B study EIP PHARMA, PI 483 phase 2B study COGRX, member advisory board GEMVAX, COGNOPTIX and 484 CORTEXZYME, member strategic innovation committee GREEN VALLEY, PI global 485 486 phase 2B study Vivoryon, PI global phase 2A study TOYAMA / FUJI FILM, PI global 487 phase 1A study IONIS, personal fees from Life Science Partners Amsterdam, outside the submitted work. JB is supported for the current study by NWO 488 (Foundation for scientific research in the Netherlands, similar to NIH and NSF) and 489 490 Co-financing by Heidelberg engineering as part of the competitive research proposal.

491	administered by the funding agency. Both these fundings are paid to institution.
492	Besides this study JB received past 36 months research grants from Heidelberg, TKI,
493	TNO, LSHM paid to institution. Personal fees from royalties through former employer,
494	Massachussets general Hospital, for IP that has been licensed to Terumo,
495	Heidelberg engineering and Spectrawave as well as fees for expert witness for a UK
496	based law firm. He is program committee member for a number of conferences,
497	unpaid. JdH, FH, MK, MK, BB, JH, AK, FV report no conflict of interest
498 499	Acknowledgements/Funding
500	We gratefully acknowledge financial support from Stichting Alzheimercentrum VUMC,
501	Alzheimer Nederland, the Dutch Technology Foundation STW (grant number 13935),
502	part of the Netherlands Organization for Scientific Research (NWO), and which is
503	partly funded by the Ministry of Economic Affairs, ISAO (grant number 14518).
504	
505	Data availability
506	Raw imaging and clinical data is available upon request
507	
508	Key Words
509	Biomarker, retina, curcumin, amyloid, Alzheimer's disease
510	

### 511 Tables

### 512 Table 1. Demographics

	Alzheimer's disease	Controls	
	<i>n</i> = 26	<i>n</i> = 14	p-value
Sex (F/M)	10/16	10/4	.047 <sup>a</sup>
Age, mean (SD)	67 (9)	71 (12)	.177 <sup>b</sup>
MMSE, median (IQR)	24 (21-26)	29 (29-30)	.000 <sup>c</sup>
CSF Aβ, median (IQR)	541 (466-744)	1328 (982-1551)	.002 <sup>c</sup>
CSF Tau, median (IQR)	320 (242-472)	208 (123-322)	.060 <sup>c</sup>
CSF pTau, median (IQR)	34 (23-44)	19 (9-30)	.035°
CSF biomarker profile (positive/negative)	20/0	3*/2	.033 <sup>a</sup>
Amyloid-PET (visual read: positive/negative)	17/0	0/13	.000ª

513

514 CSF data (presented as pg/ml) was available in 20 AD cases and 5 controls.

515 Amyloid-PET data (visual read) was available in 17 AD cases and 13 controls. <sup>a</sup>Chi

516 squared test, <sup>b</sup>Independent sample T-test, <sup>c</sup>Mann Whitney-U test. \*3 controls had a

517 borderline positive biomarker profile, with a negative amyloid-PET. Abbreviations: SD

518 = standard deviation; MMSE = mini mental state exam; IQR = interquartile range;

519 pTau = phosphorylated tau; CSF = cerebral spinal fluid.

#### Table 2 A) Demographics Longvida® Subgroup Quantitative analysis

	<u>AD</u>	<u>CN</u>	
	n = 14	n = 11	p-value
Sex (F/M)	6/8	7/4	0.302 <sup>a</sup>
Age, mean (SD)	71(9)	73(11)	0.405 <sup>b</sup>
MMSE, median (IQR)	24(19-30)	29(27-30)	<0.001°
CSF Aβ, median (IQR)	560(322-805)	1198(641-1498)	0.048 <sup>c</sup>
CSF Tau, median (IQR)	295(108-551)	247(136-364)	0.683 <sup>c</sup>
CSF pTau, median (IQR)	31(11-33)	22(11-33)	0.461 <sup>c</sup>
Amyloid-PET (visual read): (positive/negative)	7/0	0/11	<0.001ª

### **B)** Quantitative analysis

Number of increased spots	AD		CN		
	Mean	SD	Mean	SD	p-value
Macula	29.5	23.4	46.5	51.7	0.748
Temporal	40.5	28.2	47.8	45.3	0.809
Inferior	52.6	62.0	37.9	46.1	0.705
Inferior-Temporal	33.3	22.0	28.0	28.9	0.403
Superior	39.1	47.4	29.2	25.2	0.905
Superior-Temporal	44.4	35.6	44.6	36.7	1.000

Number of decreased spots	AI	כ	CN			
	Mean	SD	Mean	SD	p-value	
Macula	3.8	6.6	8.3	17.4	0.949	
Temporal	8.9	12.3	8.9	16.1	0.647	
Inferior	8.8	15.0	6.7	13.2	0.918	
Inferior-Temporal	5.2	9.8	4.7	6.0	0.926	
Superior	6.3	7.9	3.9	5.4	0.497	
Superior-Temporal	11.2	11.0	9.3	8.4	0.896	

A) CSF data (presented as pg/ml) was available in 8 AD cases and 4 controls.

530 Amyloid-PET data (visual read) was available in 7 AD cases and 12 controls. aChi

squared test, bIndependent sample T-test, cMann Whitney-U test. \*3 controls had a

- borderline positive biomarker profile, with a negative amyloid-PET. Abbreviations: AD
- 533 = Alzheimer's disease, CN =Controls, SD = standard deviation; MMSE = mini mental

state exam; IQR = interquartile range; pTau = phosphorylated tau; CSF = cerebral

535 spinal fluid.

B) Results of quantitative analyses of images obtained with 30-degree lens showing

537 the number of spots with and increased or decreased pixel value after Longvida®

538 curcumin intake compared to baseline in all retinal regions for 14 AD and 12 control

539 participants. Data is presented as mean and standard deviations. Group comparisons

540 were made using a Mann Whitney U Test.

541

# 543 **Table 3. Curcuminoids plasma levels**

	Longvida®	Theracurmin <sup>®</sup>	Novasol®
Curcumin	75.1 (70.2)	321.80 (146.1)	1108.40 (503.3)
Demethoxycurcumin	55 (62.5)	19.49 (9.7)	58.72 (28.6)
Bisdemethoxycurcumin	13.7 (12.1)	0.66 (0.3)	3.23 (2.4)
Tetrahydrocurcumin	43.6 (44.9)	234.70 (95.5)	435.4 (73.8)
Total curcuminoids	156.2(169.6)	576.6 (211.1)	1605.8 (524.6)

544

545 Plasma levels (mean ±SD) of different curcuminoids (curcumin, demethoxycurcumin,

546 bisdemethoxycurcumin and tetrahydrocurcumin) and total curcuminoids after  $\beta$ -


547 glucuronidase treatment in nanomolar (nM). Time points for serum level

548 measurement after the start of curcumin intake were 10 days for Longvida<sup>®</sup> and 5

549 days for Theracurmin<sup>®</sup> and Novasol<sup>®</sup>.


### 551 Figures






# 555 Figure 1. Visual representation of study protocol

A. Timing of imaging, blood draw and curcumin intake of cohort 1 (Longvida<sup>®</sup>, 4000
mg for 10 days), cohort 2 (Theracurmin<sup>®</sup>, 180 mg for 5 days) and cohort 3 (Novasol<sup>®</sup>,
300 mg for 4 days, 500 mg for 1 day). B. Imaging protocol of cohort 1, 2 and 3. C.
Quantitative analysis.



# 562 Figure 2. Pre- and post-curcumin retinal fluorescence images for AD and control participants using Longvida®

- 563 Pre-and post-curcumin retinal fluorescence images using blue auto fluorescence ( $\lambda$ =486nm) in 6 retinal regions in a representative 564 AD patient and control. Magnifications show incidental focal hyperfluorescence, both on baseline and after curcumin in AD and
- 565 control participants. Abbreviations: TS= temporal-superior, S= superior, T= temporal, M= macula, TI= temporal-inferior, I= inferior.





# 567 Figure 3. Plasma levels of total curcuminoids after Longvida<sup>®</sup>, Theracurmin<sup>®</sup>

# 568 and Novasol<sup>®</sup> intake measured with HPLC-MS/MS

569 Overview of plasma levels of total curcuminoids after Longvida<sup>®</sup>, Theracurmin<sup>®</sup> and

570 Novasol® intake. Curcumin, demethoxycurcumin, bisdemethoxycurcumin and

571 tetrahydrocurcumin as measured with HPLC-MS/MS after  $\beta$ -glucuronidase treatment,

572 summed as total curcuminoids in nanomolar (nM).

#### Supplemental material 574

#### Supplemental table 1. Demographics for each individual participant 575

#	Dx	Age	Sex	Sex MMSE CSF analysis Amyloid		Amyloid-PET	Curcumin				
		-			Αβ	Tau	рТаи	pTau/Aβ	CSF assay	Amyloid-FET	
1	AD	64	М	20	778	551	60	0.077	Elecsys	n.a.	Longvida
2	AD	57	М	23	342	108	10	0.029	Elecsys	n.a.	Longvida
3	AD	70	F	30	511	211	21	0.041	Elecsys	n.a.	Longvida
4	AD	72	М	22	805	316	35	0.043	Elecsys	n.a.	Longvida
5	CN	54	F	30	641	208	19	0.030	Elecsys	(-) 18F-Florbetapir	Longvida
6	AD	69	М	24	322	340	34	0.106	Elecsys	n.a.	Longvida
7	AD	56	F	21	746	215	23	0.031	Elecsys	n.a.	Longvida
8	CN	57	М	28	1323	136	11	0.008	Elecsys	(-) 18F-Florbetapir	Longvida
9	AD	59	F	19	337	156	17	0.050	Elecsys	n.a.	Longvida
10	CN	89	F	28	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Flutemetamol	Longvida
11	CN	70	F	29	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Flutemetamol	Longvida
12	AD	75	М	28	n.a.	n.a.	n.a.	n.a.	n.a.	(+) 18F-Florbetaben	Longvida
13	AD	79	М	27	n.a.	n.a.	n.a.	n.a.	n.a.	(+) 18F-Florbetaben	Longvida
14	AD	81	F	26	n.a.	n.a.	n.a.	n.a.	n.a.	(+) 18F-Florbetaben	Longvida
15	CN	80	Μ	29	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Florbetapir	Longvida
16	AD	77	М	25	n.a.	n.a.	n.a.	n.a.	n.a.	(+) 18F-Flutemetamol	Longvida
17	AD	78	М	27	n.a.	n.a.	n.a.	n.a.	n.a.	(+) 18F-Florbetaben	Longvida
18	AD	81	М	27	n.a.	n.a.	n.a.	n.a.	n.a.	(+) 18F-Florbetaben	Longvida
19	CN	66	F	29	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Flutemetamol	Longvida
20	CN	82	F	29	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Flutemetamol	Longvida
21	CN	79	М	30	1328	279	26	0.020	Elecsys	(-) 18F-Florbetapir	Longvida
22	CN	78	F	27	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Flutemetamol	Longvida
23	CN	84	М	29	1498	364	33	0.022	Elecsys	(-) 18F-Florbetapir	Longvida
24	AD	77	F	23	642	460	45	0.070	Elecsys	(+) 18F-Flutemetamol	Longvida
25	CN	66	F	30	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Flutemetamol	Longvida
26	CN	76	F	29	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Flutemetamol	Longvida
27	AD	67	М	21	548	394	35	0.064	Innotest	(+) 18F-Florbetapir	Theracurn
28	AD	61	М	20	738	307	31	0.042	Innotest	(+) 18F-Florbetaben	Theracurm
29	CN	63	F	30	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Florbetapir	Theracurm
30	AD	64	М	18	291	847	67	0.231	Innotest	(+) 18F-Florbetaben	Theracurm
31	AD	66	М	28	637	282	24	0.037	Innotest	(+) 18F-Florbetaben	Theracurn
32	CN	51	F	30	1604	110	7	0.004	Innotest	n.a.	Theracurn
33	AD	57	F	19	843	587	48	0.057	Innotest	(+) 18F-Florbetaben	Theracurn
34	AD	61	М	25	456	367	40	0.088	Innotest	(+) 18F-Florbetaben	Theracurn
35	AD	54	М	24	521	322	30	0.058	Innotest	(+) 18F-Florbetaben	Theracurm
36	AD	69	М	25	693	318	35	0.051	Innotest	(+) 18F-Florbetaben	Novasol
37	AD	65	F	24	534	477	46	0.086	Innotest	(+) 18F-Florbetaben	Novasol
38	AD	60	М	18	497	232	23	0.047	Innotest	n.a.	Novasol
39	AD	56	F	23	892	486	33	0.037	Innotest	n.a.	Novasol
40	AD	55	F	24	525	270	25	0.048	Innotest	n.a.	Novasol

576


Cohort characteristics of participants enrolled in cohort 1 (Longvida<sup>®</sup>), cohort 2 577

ratio  $\geq$  0.020 was considered as AD profile.<sup>17</sup> Abbreviations: # = Participant Number, 579

Dx = Diagnosis, MMSE = Mini-Mental State Examination, CSF = Cerebrospinal Fluid, 580

- $A\beta$  = Amyloid-beta, pTau = Phosphorylated Tau, + = positive, = negative, n.a. = not 581
- 582 available.

<sup>(</sup>Theracurmin<sup>®</sup>) and cohort 3 (Novasol<sup>®</sup>). CSF data is presented as pg/ml. pTau/Aβ 578






# 585 Supplemental Figure 1. Pre- and post-curcumin retinal fluorescence images for

### 586 AD patients and controls using Novasol®

- 587 Pre-and post-curcumin retinal fluorescence images with a 55-degree lens using blue
- auto fluorescence ( $\lambda$ =486nm) in 6 retinal regions in a representative Alzheimer's
- 589 disease (AD) patient. Abbreviations: TS= temporal-superior, S= superior, T=
- 590 temporal, M= macula, TI= temporal-inferior, I= inferior.



# Alzheimer's Disease

592

# 593 Supplemental Figure 2. Pre- and post-curcumin retinal fluorescence images for AD

### 594 patients and controls using Theracurmin®

- 595 Pre-and post-curcumin retinal fluorescence images with a 30-degree lens using blue auto
- fluorescence ( $\lambda$ =486nm) in 2 retinal regions in a representative Alzheimer's disease (AD)
- 597 patient and control. Abbreviations: M= macula, T= temporal.
- 598